Benjamin P. Linas on Muck Rack

Benjamin P. Linas

Boston
As seen in: MSN, Vox, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, The Boston Globe, JAMA Health Forum Conversations, STAT, RealClear Politics, Health Affairs, HotAir and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Benjamin P.

Contact Benjamin P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Hepatitis C Virus Screening in Pregnant and Nonpregnant Women After Universal Screening Guidelines

|
By Roshni Singh, Breanne E. Biondi, Sarah Gordon, Benjamin P. Linas
| JAMA: Journal of the American Medical Association Verified
Hepatitis C Virus Screening in Pregnant and Nonpregnant Women After Universal Screening Guidelines From 1998 to 2018, hepatitis C virus (HCV) prevalence increased from 0.34 to 5.3 cases per 1000 pregnancies.1 Guidelines for HCV were updated in March to April 2020 to include onetime screening for all adults2,3 and during each pregnancy.3 Screens for HCV in pregnancy increased after this change to 40.6% in 2021.4 We determined whether HCV screening differed among pregnant and nonpregnant women.
Open in Who Shared Issue with article?

Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus

|
By Megan Curtis, Rachel Epstein Verified, Pamela P Pei, Benjamin P. Linas
| JAMA (The Journal of the American Medical Association) Verified
Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus Key Points Question Is treating 3-year-olds with perinatally acquired hepatitis C virus (HCV) cost-effective compared with treating at older ages?
Open in Who Shared Issue with article?

Withdrawals Of COVID-19 Biologics Should Prompt Us To Reimagine Our Drug Pipeline

|
By Karim Sariahmed, Marc R. Larochelle, Benjamin P. Linas
| Health Affairs Verified
Throughout the COVID-19 pandemic, the US has put its faith and the greatest amount of resources into biomedical technology, with the use of non-pharmaceutical interventions (such as masking or behavior change) increasingly left to individuals.
Open in Who Shared Issue with article?
See all 18 licensed articles (23 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified